{
    "body": "What disease is mirtazapine predominantly used for?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/19034656", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19412502", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21810375", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21071407", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17440145", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15052512", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16280409", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21810886", 
        "http://www.ncbi.nlm.nih.gov/pubmed/12908614", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15520364", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19016570", 
        "http://www.ncbi.nlm.nih.gov/pubmed/23018612"
    ], 
    "triples": [
        {
            "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug", 
            "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/852", 
            "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB00370"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A11577558", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0600233", 
            "o": "mirtazapine"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A18168147", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }, 
        {
            "p": "http://www.w3.org/1999/02/22-rdf-syntax-ns#type", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17928971", 
            "o": "http://www.w3.org/2008/05/skos-xl#Label"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A11898470", 
            "o": "Mirtazapine"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A17977028", 
            "o": "mirtazapine"
        }, 
        {
            "p": "http://www.w3.org/2008/05/skos-xl#literalForm", 
            "s": "http://linkedlifedata.com/resource/umls/label/A11575491", 
            "o": "mirtazapine"
        }
    ], 
    "ideal_answer": [
        "Mirtazapine is predominantly used in the treatment of major depression."
    ], 
    "exact_answer": [
        "major depression"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007202", 
        "http://www.biosemantics.org/jochem#4134182", 
        "http://www.biosemantics.org/jochem#4191931"
    ], 
    "type": "factoid", 
    "id": "5156be17d24251bc05000086", 
    "snippets": [
        {
            "offsetInBeginSection": 1475, 
            "offsetInEndSection": 1565, 
            "text": "mirtazapine will make it the first-choice drug in depressive patients with gastric ulcers.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19034656", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 1695, 
            "offsetInEndSection": 2460, 
            "text": "If antidepressants are used to treat insomnia, sedating ones should be preferred over activating agents such as serotonin reuptake inhibitors. In general, drugs lacking strong cholinergic activity should be preferred. Drugs blocking serotonin 5-HT2A or 5-HT2C receptors should be preferred over those whose sedative property is caused by histamine receptor blockade only. The dose should be as low as possible (e.g. as an initial dose: doxepin 25 mg, mirtazapine 15 mg, trazodone 50 mg, trimipramine 25 mg). Regarding the lack of substantial data allowing for evidence-based recommendations, we are facing a clear need for well designed, long-term, comparative studies to further define the role of antidepressants versus other agents in the management of insomnia.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/19016570", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 770, 
            "offsetInEndSection": 970, 
            "text": "second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger than 19 years with MDD, OCD, or non-OCD anxiety disorders.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17440145", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 731, 
            "offsetInEndSection": 897, 
            "text": "patients 65 years or older with major depression. METHODS: Antidepressant therapy with 15 to 45 mg/d of mirtazapine (n = 124) or 20 to 40 mg/d of paroxetine (n = 122)", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15520364", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 521, 
            "offsetInEndSection": 710, 
            "text": "A case report involving linezolid with citalopram and mirtazepine in the precipitation of serotonin syndrome in a critically ill bone marrow transplant patient is described in this article.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16280409", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2266, 
            "offsetInEndSection": 2885, 
            "text": "other antidepressants was associated with the highest HRs for all-cause mortality (1.66, 95% CI 1.56 to 1.77), attempted suicide/self-harm (5.16, 95% CI 3.90 to 6.83), stroke/TIA (1.37, 95% CI 1.22 to 1.55), fracture (1.63, 95% CI 1.45 to 1.83) and epilepsy/seizures (2.24, 95% CI 1.60 to 3.15) compared with when antidepressants were not being used. TCAs did not have the highest HR for any of the outcomes. There were also significantly different associations between the individual drugs for seven outcomes, with trazodone, mirtazapine and venlafaxine associated with the highest rates for several of these outcomes.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21810375", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 2237, 
            "offsetInEndSection": 2569, 
            "text": "But when trazodone, amitriptyline or mirtazapine were used to treat depression, respectively, 92.3, 55.5 and 44.5 % of prescribed dosages were below the MED. In the indication of insomnia, most of the time, trazodone (90.5 %) or mirtazapine (5.4 %) were used, and in lower dosages than those required for depression treatment (<MED)", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/23018612", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 997, 
            "offsetInEndSection": 1089, 
            "text": "Mirtazapine was the most common AD in 2001, followed by citalopram, sertraline, and doxepin.", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15052512", 
            "endSection": "sections.0"
        }, 
        {
            "offsetInBeginSection": 350, 
            "offsetInEndSection": 391, 
            "text": "antidepressant treatment with mirtazapine", 
            "beginSection": "sections.0", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/12908614", 
            "endSection": "sections.0"
        }
    ]
}